+357 96 030922
info@marketpublishers.com

Japan Cancer Drug Pipeline Analysis

https://marketpublishers.com/r/J24D0192D19EN.html
Date: January 2014
Pages: 557
Price: US$ 1,500.00 (Single User License)
ID: J24D0192D19EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased trend of forming strategic partnerships would be a major driver of the industry. Additionally, Japan has taken many steps to improve the drug lag system. With the increasing inclusion of Japanese in the global Phase III trials, the drug lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia.

Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making.

“Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of various cancers. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to

+357 96 030922
info@marketpublishers.com

identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "Japan Cancer Drug Pipeline Analysis" research report:

Drug Profile Overview

Alternate Names for Drug

Active Indication

Phase of Development

Mechanism of Action

Brand Name

Patent Information

Orphan Designation by Indication, Country & Organisation

Country for Clinical Trial

Owner / Originator/ Licensee/Collaborator

Administrative Route

Drug Class • ATC Codes

Number of Cancer Drugs in Pipeline by Clinical Phase:

Research: 23

Preclinical: 67

Clinical: 3

+357 96 030922
info@marketpublishers.com

Phase-I: 98

Phase-I/II: 15

Phase-II: 26

Phase-II/III: 3

Phase-III: 37

Preregistration: 8

Registered: 8

Marketed: 90

Unknown: 1

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:

Alternate Names

Originator & Owner

Collaborator

Technology Provider

Licensee

Highest Development Phase

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

About

Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.

With the ageing population rapidly rising in Japan, cancer has become of the leading cause of concern. Since 1982, Japan has recorded a mortality rate of one in three persons dying due to cancer. The Japanese government has been an important contributor in taking efforts towards controlling the spread of this disease. There has been significant work done by the Ministry of Health and Welfare, the Ministry of Education, Science, Culture and Sports and the Science and Science Technology Agency in this space.

The Japanese market for cancer-related drugs including anticancer agents, colony-stimulating factors, antiemetics and pain relievers was valued approximately at xx billion yen in 2012. An increasing number of patients and incidence rates are the major factors driving this market. This market is expected to record a CAGR of 6-9% to reach an estimated value of xx billion yen by 2017.

Of the total cancer drug market, the anticancerdrug segment accounts for close to 85%. Another segment in the market namely the oncology agents market, which includes hormone therapies, molecule targeted drugs, antimetabolites, microtubule inhibitors, platinum preparations, anticancer antibiotics and immuno-potentiators has been growing at a CAGR of 7-9% in recent years.

The major reasons for the positive growth of Japanese cancer market is attributed to the success of Avastin (bevacizumab) and Tarceva (erlotinib) launched by Chugai, coupled with the launches of Nexavar (sorafenib), Sutent (sunitinib) and Elplat (oxaliplatin) by Bayer, Pfizer and Yakult respectively. The total sales of these agentsare expected to cross xx billion yen by 2017 by growing at a very rapid rate. The development of new drugs and the new targeted therapies has been a major driver of growth in this market.

Owing to the increased level of awareness of the significance of palliative care among Japanese physicians and patients has led to a high growth in the revenues of cancer painkillers, which include opioids and non-opioids. It is most likely that this segment

+357 96 030922
info@marketpublishers.com

would record a growth rate of close to xx% in the years to come to reach approximately xx billion yen by 2017.

With the successful launch of the targeted therapeutics segment and identifying the extensive benefits of these new therapies, there has been the rise of novel strategies for treatment which include more effective combinations of chemotherapy and hormonal drugs. These are likely to drive the demand for drugs in the cancer treatment market in Japan. On these lines, it is most likely that the segment of targeted therapies alone could possibly experience the maximum significant growth over the years to come which would inturn reflect on the increasing importance of this segment to the overall market.

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased trend of forming strategic partnerships would be a major driver of the industry. Additionally, Japan has taken many steps to improve the drug lag system.

With the increasing inclusion of Japanese in the global Phase III trials, the drug lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia. Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making.

Thus, all these efforts are likely to provide the required push to the cancer market in Japan which is set to be placed on a growth trajectory.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Japan Cancer Drug Pipeline Analysis

Product link: https://marketpublishers.com/r/J24D0192D19EN.html

Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/J24D0192D19EN.html